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Background-—Implantable cardioverter-defibrillators (ICDs) are widely employed for the prevention of sudden cardiac death.
Despite technological improvements, patients often need to undergo generator replacement, which entails the risk of
periprocedural complications. Our aim was to estimate the service life of ICDs over a 10-year interval and to assess the main
causes of replacement on the basis of data from the National ICD Registry of the Italian Society of Arrhythmology and Cardiac
Pacing (AIAC).
Methods and Results-—The registry includes data from over 400 hospitals in Italy. We included all patients who underwent device
replacement from calendar years 2007 to 2016. The median service life of the ICDs and its trend over the years was estimated
across the 3 types of devices (single-chamber, dual-chamber, cardiac resynchronization therapy defibrillator) and the indication to
implantation. The causes of replacement were also analyzed. We included 29 158 records from 27 676 patients (80.9% men; mean
age at device replacement 65.812.0 years). The median service life was 57.3 months (interquartile range 27.8 months). Over the
years, service life showed an increasing trend. The majority of patients underwent elective replacement because of battery end of
life, and over the years there was a significant reduction of replacement for recalls, erosion/infections, and cardiac
resynchronization therapy upgrading.
Conclusions-—Our data from a large single-nation population showed that the trend of ICD service life, independently from ICD
type, indication, and settings, significantly improved over time. Moreover, there was a striking reduction of interventions for
upgrading and infection/erosion. This favorable trend has important clinical, organizational, and financial implications. ( J Am
Heart Assoc. 2019;8:e012759. DOI: 10.1161/JAHA.119.012759.)
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Implantable cardioverter-defibrillators (ICDs) and cardiacresynchronization therapy defibrillators (CRT-Ds) have
become a landmark option for the prevention of sudden
cardiac death in patients at risk for fatal ventricular arrhyth-
mias.1,2 Registries from clinical practice have confirmed in
larger scale the efficacy of ICD therapy in the setting of both
primary and secondary prevention.3–5 The growing mismatch
between the service life of the devices and patient survival is
already a well-known issue.6 Moreover, previous single-center
and few-center studies have demonstrated highly variable ICD
longevity according to device manufacturers.7–11 Technology
improvements, in particular on the front of battery longevity,
have tried to solve the problem, but ICD and CRT-D service life
may still be shorter than patients’ average survival. This
implies the need for generator replacement, which entails the
risk of periprocedural complications (damage of the leads,
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bleeding, and infections) and negatively impacts the cost-
efficacy of the devices.12–16
The aim of this study was to estimate over a 10-year
interval the trend of service life of ICD and CRT-D generators,
which also reflects device longevity, and to evaluate the main
causes of replacement on the basis of data from the National
ICD Registry of the Italian Society of Arrhythmology and
Cardiac Pacing (AIAC), which regularly collects main technical
and clinical information on all ICD and CRT-D implantations
performed in the majority of Italian hospitals.
Materials and Methods
Because of the sensitive nature of the data collected for this
study, requests to access the data set from qualified
researchers trained in human subject confidentiality protocols
may be sent to the IRCAB Foundation at ircab.founda-
tion@asuiud.sanita.fvg.it.
Patients gave informed consent to sensible data collection
and its possible use, in anonymized form, for research
purposes at the time of first implantation with an ICD/CRT-D.
Our institutional review board has previously approved the
research activities of the Italian National ICD Registry.
We included all patients from the Italian National ICD
Registry who underwent device replacement of ICD/CRT-Ds
from calendar years 2007 to 2016. In fact, complete and
validated data are so far available in the Registry up to
calendar year 2016 and we decided a priori to include a 10-
year period. Along the entire period, the main indications to
replacement were explored according to the European
Patient-Implantable Cardioverter/Defibrillator Identification
Card (EURID) form.17–19
The mean duration from implantation to replacement was
calculated by subdividing the patients according to device
characteristics (single-chamber ICD [ICD-VR], dual-chamber
ICD [ICD-DR], or CRT-D), indications to implantation (primary
or secondary prevention), and year of device replacement.
The Italian National ICD Registry is a centrally held
database in which all participating centers (over 400 hospitals
that perform about 95% of ICD/CRT-D implantations in Italy)
voluntary provide clinical and technical data on every patient
and device implanted.17,19
Data are reported in the registry using EURID implant
forms and retrieved by mail after implantation, replacement,
and explantation procedures. Validation of data is performed
using a 2-step protocol: first, at the time of data entry, data
are checked for formal consistency, and, then, at the time
when the annual report is performed, data are evaluated for
internal consistency. Of note, for internal policy the Italian
National ICD registry does not publicly report data subdivided
by device manufacturer.
The causes of replacement were grouped into 4 categories:
(1) elective replacement for battery end of life; (2) system
recall according to specific manufacturer advisory or system
malfunction detected at the follow-up center; (3) upgrading to
CRT device; and (4) system infection or pocket erosion.
For the analysis IBM SPSS Statistics version 20 and R
version 3.5.220 powered by the rms package version 5.1-221
were employed. Data analysis included basic descriptive
statistics, with categorical variables usually reported in
frequencies (percentages) and absolute numbers, and contin-
uous variables reported as meanSD or median values and
interquartile range (IQR), as appropriate. P values have been
calculated, whenever appropriate, using ANOVA or Wilcoxon-
Kruskal–Wallis test for continuous variables and Pearson chi-
square test for categorical variables. The significance cutoff of
P was fixed to 0.05. The mean expected temporal trends of
device longevity were estimated using a generalized linear
model with gamma distribution and log link function to
account for the positive values, the skewness, and long tails in
the distribution of devices’ time of duration. To take into
account the heteroskedasticity, 1000 bootstrap evaluations of
the model, clustered at the subject level, were evaluated to
estimate 95% CIs.22
Results
In the decade 2007–2016 the Italian ICD Registry collected
29 158 records (80.9% men; mean age 65.212.1 years)
pertaining to 27 676 patients, who underwent ICD/CRT-D
device replacement. Among these records, 18 814 (64.5%;
Clinical Perspective
What Is New?
• This is the first article to analyze the trend of service life of
implantable cardioverter-defibrillators/cardiac resynchro-
nization therapy defibrillators over the years on a whole-
nation basis.
• We showed an incremental trend of implantable car-
dioverter-defibrillator/cardiac resynchronization therapy
defibrillator service life over the years in the whole
population and in a subanalysis subdividing the population
according to the type of device and the indications to first
implantation.
What Are the Clinical Implications?
• The shown incremental trend in service life positively
impacts the cost-effectiveness of implantable cardioverter-
defibrillator/cardiac resynchronization defibrillator therapy,
potentially allowing for better use of the resources saved.
DOI: 10.1161/JAHA.119.012759 Journal of the American Heart Association 2
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mean age at device replacement 66.211.5 years) had
received their first ICD/CRT-D for primary prevention and
10 344 (35.5%; mean age at device replacement
64.113.1 years) for secondary prevention.
Table 1 shows the distribution of records according to the
main clinical indication and the characteristics of the
implanted device. Overall, the largest proportion of patients
underwent implantation with a CRT-D (47.5%), but this
distribution was strongly influenced by the larger subgroup
of patients implanted for primary prevention. In fact, patients
undergoing implantation for secondary prevention received
the 3 ICD types (VR, DR, CRT-D) in substantially equally
distributed percentages.
Table 2 shows the distribution of records according to the
underlying heart disease and device characteristics. Overall,
the majority of patients had ischemic cardiomyopathy and the
second most represented cause was nonischemic cardiomy-
opathy. Conversely, nonischemic cardiomyopathy was
preponderant in the subgroup of patients implanted with a
CRT-D. As expected, patients undergoing implantation for an
idiopathic, purely arrhythmic disease were more represented
in the subgroup of patients implanted with an ICD-VR.
The median service life of the replaced devices was 57.3
months (IQR 27.8 months). In detail, in those undergoing
implantation for primary prevention, the median service life
was 56.8 months (IQR 27.0 months), whereas in those
undergoing implantation for secondary prevention, the median
service life was 58.0 months (IQR 29.4 months) (P<0.001).
The service life of CRT-D devices was significantly lower than
the service life of ICD-VR and ICD-DR devices, independently
from the indication to ICD implantation (Figure 1).
Over the years, device service life showed an increasing
trend that remains evident among the 3 types of ICDs and
among the 2 main indications to implantation. In particular,
the median service life of the ICD replaced in 2007 was
45.8 months (IQR 28.6 months), whereas the median service
life of the devices replaced in 2016 was 68.1 months (IQR
27.7 months; P<0.001), with a net increase of 22.3 months
(relative increase 48.7%). According to ICD types, the net
increase of longevity was, respectively, 32.6 months (relative
increase 59%) in ICD-VR–treated patients, 28.7 months
(relative increase 59.4%) in ICD-DR–treated patients, and
25.1 months (relative increase 68.9%) in the CRT-D group
(Figures 2 and 3, Table S1).
The main replacement causes are summarized in Table 3.
The majority of devices were replaced because of battery end
of life, in particular in CRT-Ds (over 91% for both primary and
secondary prevention). The proportion of replacements/
explantations for recalls and infections/erosion was low and
marginal. Conversely, the proportion of replacements for
device CRT upgrading was important, in the range of 10%,
but was obviously limited to ICD-VR and ICD-DR systems.
Table 1. Distribution of Patients Who Underwent ICD
Replacement in the Period 2007–2016, According to the Type
of Implanted Device and Indication to First ICD Implantation
Primary Prevention Secondary Prevention Combined
ICD-VR 3797 (20.2) 3278 (31.7) 7075 (24.3)
ICD-DR 4733 (25.1) 3478 (33.6) 8211 (28.2)
CRT-D 10 284 (54.7) 3588 (34.7) 13 872 (47.5)
Combined 18 814 (100) 10 344 (100) 29 158 (100)
Data are expressed as count (percentage). CRT-D indicates cardiac resynchronization
therapy defibrillator; ICD, implantable cardioverter-defibrillator; ICD-DR, dual-chamber
implantable cardioverter-defibrillator; ICD-VR, single-chamber implantable cardioverter-
defibrillator. P<0.001.
Table 2. Demographic Characteristics of the Population and Distribution of Patients According to Underlying Heart Disease and
Device Characteristics
ICD-VR ICD-DR CRT-D Combined
Age, y 61.314.4 64.312.6 67.79.7 65.212.1
Men 5814 (82.2) 6849 (83.4) 10 916 (78.7) 23 579 (80.9)
Ischemic cardiomyopathy 3797 (53.7) 4447 (54.2) 5836 (42.1) 14 080 (48.3)
Nonischemic cardiomyopathy 2157 (30.5) 2612 (31.8) 7393 (53.3) 12 162 (41.7)
Hypertrophic cardiomyopathy 185 (2.6) 296 (3.6) 80 (0.6) 561 (1.9)
Arrhythmogenic ventricular cardiomyopathy 125 (1.8) 118 (1.4) 30 (0.2) 273 (0.9)
Other cardiomyopathies 241 (3.4) 304 (3.7) 284 (2.0) 829 (2.8)
Valvular heart disease 114 (1.6) 121 (1.5) 249 (1.8) 484 (1.7)
Long QT syndrome 60 (0.8) 74 (0.9) 0 (0.0) 134 (0.5)
Idiopathic arrhythmias 396 (5.6) 239 (2.9) 0 (0.0) 635 (2.2)
Data are expressed as meanSD or count (percentage), as appropriate. CRT-D indicates cardiac resynchronization therapy defibrillator; ICD-DR, dual-chamber implantable cardioverter-
defibrillator; ICD-VR, single-chamber implantable cardioverter-defibrillator.
DOI: 10.1161/JAHA.119.012759 Journal of the American Heart Association 3
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Over the years there was a significant (P<0.001) reduction
in replacement for recalls, erosion/infections, and upgrading,
and, consequently, a relative increase in replacements for
battery end of life (Table 4).
Discussion
Data from our large single-nation population, including more
than 29 000 replacements, showed that ICD service life,
independently from ICD type, indication, and settings, signif-
icantly improved over a 10-year period and that the causes of
replacement evolved with a striking reduction of interventions
for CRT upgrading and infection/erosion in favor of interven-
tions for battery end of life. The relative increase in device
longevity across the years was particularly evident for CRT-D,
a subset of high-cost and more sophisticated devices with
high technological evolution.
The importance of increasing the longevity of ICDs appears
obvious both in the setting of purely electric diseases, clinical
conditions where patient survival may be similar to the normal
population, and in the cohort of patients with left ventricular
dysfunction and heart failure, because long-term outcome of
these patients has been recently improved with new phar-
macologic agents and appropriate clinical management.
Extension of device longevity may reduce the mismatch that
was demonstrated in the past between patient survival and
ICD/CRT-D service life.16 An increase of device longevity
could be obtained by improved device technology (both
hardware and software) and battery chemistry and determines
both clinical and economic benefit, with an important impact
on reducing procedural complications and long-term cost of
ICD therapy.13–15
In our experience, the observed reduction of interventions
for device system CRT upgrading could be explained by
improvements in the initial choice of ICD type, which was
probably induced by evidence that periprocedural morbidity is
higher in patients who undergo an upgrade compared with
patients who undergo replacement of the generator.23
Figure 1. Distribution of service life (months) of implantable cardioverter-defibrillator (ICD)/cardiac
resynchronization therapy defibrillator (CRT-D) devices according to ICD indication and device characteristics.
Box borders represent the first and third quartiles of the distribution, the segment inside the box represents the
median value of the distribution, the vertical lines above and below the box extend up to 1.5 times the
interquartile range (IQR; ie, the height of the box), and observations that exceed 1.5 times the IQR are considered
outliers and are drawn as singular dots. Boxes are drawn with widths proportional to the square roots of the
number of observations in the groups. In detail, the median service life was: primary prevention: ICD–single-
chamber device (VR) 67.5 months (IQR 37.6 months), ICD–dual-chamber device (DR) 64.6 months (IQR
28.0 months), and CRT-D 51.9 months (IQR 20.5 months); secondary prevention: ICD-VR 66.2 months (IQR
33.6 months), ICD-DR 61.9 months (IQR 27.2 months), and CRT-D 49.1 months (IQR 20.8 months).
DOI: 10.1161/JAHA.119.012759 Journal of the American Heart Association 4
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Conversely, in our registry, the reduction of explantations for
erosion/infections could be justified by the improvement of
surgical techniques and equipment, as well as by a more
diffuse and increasing expertise across the implanting
centers. ICD or CRT-D replacement for system recalls could
also have been reduced by large implementation after the
year 2012 of remote monitoring, which allows a stricter
follow-up permitting postponement of replacement.24–27 The
reduction of the number of replacements has important
clinical implications related to a potential decrease in the risk
of complications and specifically of device system infections
that any replacement may imply according to a series of risk
factors.28,29
The service life of ICDs is determined by a multiplicity of
factors and is difficult predict a priori. Therefore, data from
“real-world” registries can be particularly helpful as they have
already been shown to accurately describe the actual impact
of ICD therapy on ordinary populations.3,4 In the past years,
several studies on ICD longevity have been published, with
most being single-center or multicenter studies collecting
data from <50 participating centers.8–10,30,31
With respect to previously published data, it must be noted
that proper comparison of device service life between
different studies is difficult to obtain because of inhomogene-
ity of patients included and data presentation. Thijssen et al30
reported longevity as a mean value of 5.00.1 years and
included 4673 patients who underwent implantation with an
ICD from calendar year 1996 to calendar year 2011.
Analyzing data from a population of 3436 patients from
calendar year 1994 to calendar year 2004, von Gunten et al9
showed that 69.8% of ICDs were still operative after 5 years.
Zanon et al31 estimated a median service life of 5.9 years
(IQR 2.0 years) in ICD-VR and ICD-DR and of 4.9 years (IQR
1.7 years) in CRT-D explanted from March 2013 to May 2015.
Conversely, Manolis et al8 assessed ICD service life over a
20-year period among 685 patients, with the majority of them
Figure 2. Trends of the implantable cardioverter-defibrillator (ICD) service life distributions across the years according to ICD type. CRT-D
indicates cardiac resynchronization therapy defibrillator; DR, dual-chamber device; VR, single-chamber device.
DOI: 10.1161/JAHA.119.012759 Journal of the American Heart Association 5
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undergoing implantation with an ICD for secondary
prevention; they estimated a mean service life of
58.318.7 months. In another single-center study, the mean
longevity of 1665 devices implanted in 1272 patients
between calendar year 1998 and calendar year 2010 ranged
from 5.2 to 5.7 years according to different manufacturers.10
Device type and percentage of pacing, but not pacing output
and ICD shocks, had an influence on battery longevity.10
Data from the literature confirm our finding that longevity of
CRT-D is shorter than that of ICD-VR and ICD-DR, which can be
intuitively explainedby thehigher percentageofpacing, especially
left ventricular pacing, and by device complexity.13,16,31
In addition, battery end of life is the most frequent cause of
device replacement interventions in previous studies.9,30,31
Only Thjissen et al30 found higher percentages of substitution
for erosion/infections and recalls, but their population
included patients who underwent implantation with an ICD
from calendar year 1996.
The trend toward a prolongation of service life over the
years among all ICD types has been highlighted in previous
Figure 3. Model fitted by implantable cardioverter-defibrillator (ICD) type: trend of the expected service
life (in months) as modeled by the years. Vertical bars represent the original data. Shadows represent the
95% CI for the drawn lines. CRT-D indicates cardiac resynchronization therapy defibrillator; DR, dual-
chamber device; VR, single-chamber device.
Table 3. Causes of Replacement According to Device Characteristics and Indication to Implantation
Primary Prevention Secondary Prevention
CombinedICD-VR ICD-DR CRT-D ICD-VR ICD-DR CRT-D
Battery end of life 2650 (69.8) 3502 (74.0) 9470 (92.1) 2297 (70.1) 2602 (74.8) 3302 (92.0) 23 823 (81.7)
Recall/system malfunction 35 (0.9) 59 (1.2) 120 (1.2) 53 (1.6) 51 (1.5) 36 (1.0) 354 (1.2)
CRT upgrading 781 (20.6) 824 (17.4) 0 (0.0) 702 (21.4) 565 (16.2) 0 (0.0) 2872 (9.8)
Infection/erosion 46 (1.2) 80 (1.7) 182 (1.8) 38 (1.2) 66 (1.9) 73 (2.0) 485 (1.6)
Not available 285 (7.5) 268 (5.7) 512 (5.0) 188 (5.7) 194 (5.6) 177 (4.9) 1624 (5.6)
Data are expressed as count (percentage). All comparisons were significant at the P<0.001 level. CRT indicates cardiac resynchronization therapy; CRT-D, cardiac resynchronization
therapy defibrillator; ICD-DR, dual-chamber implantable cardioverter-defibrillator; ICD-VR, single-chamber implantable cardioverter-defibrillator.
DOI: 10.1161/JAHA.119.012759 Journal of the American Heart Association 6
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studies and is attributable to technology improvements.9,30
The long-term effects of up-to-date ICD technology and
programming should be evaluated in the future and compared
with the longevity predicted by industry models.32
Since the cost of ICD therapy is typically characterized by
the upfront cost of the device, at implant or replacement,33
the positive trend in service life that emerges in our analysis
has important implications for the organization of care and for
the financial resources spent on ICD therapy. The population
in Western countries is becoming older34 and the lengthening
of ICD service life may allow distribution of the saved
resources to a wider patient population.
Study Limitations
The trend of service life that we found could be explained by
the characteristics of our “real-world” analyses, which
includes the device replacements collected in a whole
nation. It is plausible that a significant percentage of our
patients received less device optimization if compared with
patients enrolled in prospective studies and performed in
selected centers. In particular, the Italian ICD registry did not
consider the impact on service life of large-scale implemen-
tation of up-to-date device programming, including long
detection strategies and shock-avoiding device settings.35–37
In addition, the effects on device longevity of the different
pacing programming, percentage of atrial and ventricular
pacing during the follow-up, and number and type of ICD
interventions (shock and/or ATP) were not analyzed in our
study because this information is not included in the queries
of the Italian ICD registry. Finally, we did not consider the
ICD and CRT-D service life according to the specific
manufacturer because this type of analysis was not planned
among the activities of the Italian ICD registry and could
have been distorted by important technological inhomo-
geneities across a 10-year period. Similarly, other large and
official ICD registries have not included vendor analysis in
their reports.38,39
Conclusions
The 10-year analysis from 2007 to 2016 of the National Italian
ICD Registry showed that around 29 000 patients underwent
ICD and CRT-D replacement and that the trend of ICD service
life, independently from ICD type, indication, and settings,
significantly improved over time. Moreover, the causes of
replacement evolved over the 10-year period with a striking
reduction of interventions required for CRT upgrading and
infection/erosion in favor of battery end of life. The positive
trend that emerged has important and favorable clinical,
organizational, and financial implications.
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Table S1. Service life of the devices (months) subdivided per year of replacement and according to the ICD 
type and ICD indications.  
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